In the published article, there was an error in the affiliation of the first author. Instead of “Preventive Oncology, Sammprada Cancer Hospital, Bangalore, India”, it should be “Preventive Oncology, Healthcare Global, Bangalore, India”.
In the published article, there was an error in the affiliation of the third author. Instead of “Preventive Oncology, Sammprada Cancer Hospital, Bangalore, India”, it should be “Medical Oncology, Healthcare Global, Bangalore, India”.
The corresponding author email was erroneously given as: vinodramani77@gmail.com. The correct email address is: drvinod.r@hcgel.com.
The original version of this article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
metformin, survival analysis, triple negative breast neoplasm, remission, neoadjuvant
Citation
Ramani VK, Sadashivaiah AB and Naik R (2025) Correction: Neoadjuvant chemotherapy with or without metformin in early-stage or locally advanced (non-metastatic) triple negative breast cancer—an open-label phase 2 randomized controlled trial. Front. Oncol. 15:1658958. doi: 10.3389/fonc.2025.1658958
Received
03 July 2025
Accepted
07 July 2025
Published
01 August 2025
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
15 - 2025
Updates
Copyright
© 2025 Ramani, Sadashivaiah and Naik.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Vinod K. Ramani, drvinod.r@hcgel.com
†ORCID: Vinod K. Ramani, orcid.org/0000-0002-6531-9579
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.